These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22441650)

  • 1. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
    Lillie PJ; Berthoud TK; Powell TJ; Lambe T; Mullarkey C; Spencer AJ; Hamill M; Peng Y; Blais ME; Duncan CJ; Sheehy SH; Havelock T; Faust SN; Williams RL; Gilbert A; Oxford J; Dong T; Hill AV; Gilbert SC
    Clin Infect Dis; 2012 Jul; 55(1):19-25. PubMed ID: 22441650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of CD8
    Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A
    Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
    Boyd AC; Ruiz-Hernandez R; Peroval MY; Carson C; Balkissoon D; Staines K; Turner AV; Hill AV; Gilbert SC; Butter C
    Vaccine; 2013 Jan; 31(4):670-5. PubMed ID: 23200938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
    Antrobus RD; Berthoud TK; Mullarkey CE; Hoschler K; Coughlan L; Zambon M; Hill AV; Gilbert SC
    Mol Ther; 2014 Jan; 22(1):233-8. PubMed ID: 23831594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
    Berthoud TK; Hamill M; Lillie PJ; Hwenda L; Collins KA; Ewer KJ; Milicic A; Poyntz HC; Lambe T; Fletcher HA; Hill AV; Gilbert SC
    Clin Infect Dis; 2011 Jan; 52(1):1-7. PubMed ID: 21148512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
    Powell TJ; Peng Y; Berthoud TK; Blais ME; Lillie PJ; Hill AV; Rowland-Jones SL; McMichael AJ; Gilbert SC; Dong T
    PLoS One; 2013; 8(5):e62778. PubMed ID: 23658773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.
    Mullin J; Ahmed MS; Sharma R; Upile N; Beer H; Achar P; Puksuriwong S; Ferrara F; Temperton N; McNamara P; Lambe T; Gilbert SC; Zhang Q
    Vaccine; 2016 Mar; 34(14):1688-95. PubMed ID: 26902548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
    Magini D; Giovani C; Mangiavacchi S; Maccari S; Cecchi R; Ulmer JB; De Gregorio E; Geall AJ; Brazzoli M; Bertholet S
    PLoS One; 2016; 11(8):e0161193. PubMed ID: 27525409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
    Antrobus RD; Coughlan L; Berthoud TK; Dicks MD; Hill AV; Lambe T; Gilbert SC
    Mol Ther; 2014 Mar; 22(3):668-674. PubMed ID: 24374965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.
    Vitelli A; Quirion MR; Lo CY; Misplon JA; Grabowska AK; Pierantoni A; Ammendola V; Price GE; Soboleski MR; Cortese R; Colloca S; Nicosia A; Epstein SL
    PLoS One; 2013; 8(3):e55435. PubMed ID: 23536756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice.
    Yang P; Wang W; Gu H; Li Z; Zhang K; Wang Z; Li R; Duan Y; Zhang S; Wang X
    Antiviral Res; 2014 Nov; 111():1-7. PubMed ID: 25173575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
    Johansson BE; Kilbourne ED
    Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A one-size-fits-all flu vaccine?
    Kaiser J
    Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732
    [No Abstract]   [Full Text] [Related]  

  • 18. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.
    Chang H; Huang C; Wu J; Fang F; Zhang W; Wang F; Chen Z
    Virol J; 2010 Aug; 7():197. PubMed ID: 20727202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.
    Li Z; Gabbard JD; Mooney A; Gao X; Chen Z; Place RJ; Tompkins SM; He B
    J Virol; 2013 May; 87(10):5985-93. PubMed ID: 23514880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies.
    Price GE; Lo CY; Misplon JA; Epstein SL
    J Virol; 2022 Jun; 96(12):e0032022. PubMed ID: 35638848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.